|
Protocol ID |
Official Title |
PI Name |
Lead CRC |
Disease Site |
Phase |
|
EA6141 ClinicalTrials.gov: NCT02339571 |
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma | S. Ghamande | Inquiries | Melanoma | II/III |
|
EA6134 ClinicalTrials.gov: NCT02224781 |
A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma | S. Ghamande | Inquiries | Melanoma | III |
